Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Quarterly Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70, Yahoo Finance reports. The company had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN traded down $0.62 during trading hours on Wednesday, hitting $14.57. The stock had a trading volume of 1,664,414 shares, compared to its average volume of 909,708. The company has a market capitalization of $1.27 billion, a P/E ratio of -5.65 and a beta of -1.51. The firm’s 50-day moving average price is $14.01 and its two-hundred day moving average price is $14.84. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DAWN. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Friday, July 26th. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Insider Activity at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,253 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $52,308.24. Following the completion of the sale, the general counsel now owns 21,731 shares of the company’s stock, valued at approximately $349,434.48. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, General Counsel Adam Dubow sold 3,253 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $52,308.24. Following the completion of the sale, the general counsel now directly owns 21,731 shares in the company, valued at approximately $349,434.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 9,154 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $17.85, for a total value of $163,398.90. Following the completion of the sale, the chief executive officer now owns 642,602 shares of the company’s stock, valued at $11,470,445.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,300 shares of company stock valued at $1,181,765. 8.40% of the stock is owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.